The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as ...
Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with heart failure, according to research presented today at Heart Failure 2024, a scientific ...
Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...
There is impaired functional capacity in patients with type 2 diabetes and stage B heart failure characteristics. Patients with type 2 diabetes and stage B heart failure characteristics have impaired ...
The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...
Patients with atrial fibrillation (AF) gain clinical benefit from exercise-based cardiac rehabilitation without experiencing a rise in serious adverse events, according to a contemporary look at the ...
Zacks Investment Research on MSN
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
Cytokinetics, Incorporated CYTK announced that the FDA approved its lead pipeline candidate, aficamten, for the treatment of ...
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMFDA Approval Based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback